C11749: Novel Collagen Targeting for Imaging and Therapeutic ApplicationsNovelty:
This technology employs collagen mimetic peptides to target denatured collagen in vivo for imaging and treatment of cancer and other diseases affecting the collagen matrix.
Value Proposition:
There are currently no available means of targeting a denatured collagen matrix in vivo for imaging or therapeutic purposes. The ability to view the collagen matrix in diseased tissue could lead to important discoveries for the treatment of cancer and other tissue degenerative diseases, as well as for tissue remodeling processes. This invention uses collagen mimetic peptides that bind to denatured collagen to enable targeting of the collagen matrix. Other advantages include:
• Ability to tune and functionalize peptides based on intended application
• Can be used either in vivo or in vitro
• Targeted collagen remains undisturbed by the binding mechanism
• Novel method to advance understanding of cancer and other diseases affecting the collagen matrix
Technical Details:
Johns Hopkins researchers have developed a series of collagen mimetic peptides that target and bind to MMP cleaved and denatured collagen. The binding can be triggered either by light or by temperature, depending on whether the peptides are used in vivo or in vitro. These collagen mimetic peptides are of low molecular weight and have tunable properties depending on imaging or therapeutic applications. Further, the binding mechanism of these peptides does not interfere with the natural structure of the collagen itself, thus facilitating accurate imaging of the collagen matrix as is.
Looking for Partners:
To develop and commercialize the technology as novel means of targeting denatured collagen in vivo and in vitro for imaging and therapeutic purposes.
Stage of Development:
Discovery
Data Availability:
Under CDA/NDA
Publications/Associated Cases:
Not available at this time.
